RV 144

Status:Completed
Phase:III
Principal Investigator(s):Supachai Rerks-Ngarm
Objective:To determine whether immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E prevent HIV infection in healthy Thai volunteers.Results: The ALVAC-HIV and AIDSVAX B/E vaccine regimen was found to be safe, well tolerated and suitable for potential large-scale use in Thailand.Last updated September 14, 2022
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Arms and Assigned Interventions
DescriptionALVAC-HIV vCP1521 + AIDSVAX 1cc injected into left deltoid muscle at day 0,weeks 4, 12, 24 Prime/Boost Vaccination
Mode of DeliveryIntramuscular
ARMsExperimental
Results: Safety and reactogenicity of canarypox ALVAC-HIV
Official Code: NCT00223080
Related Publications:
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial
CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants
Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials
Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults
Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand
Foundations for a Phase III human immunodeficiency virus vaccine trial: A decade of Thai-U.S. Army collaborative research
Trial Sponsors: EMMES, Henry M Jackson Foundation, Sanofi Pasteur MSD, Thailand Ministry of Health, US Military HIV Research Program, VaxGen, Walter Reed Army Institute of Research (WRAIR)
Start Date
End Date
October 1, 2003
June 30, 2009
Enrollment:16,402
Age range: 18 Years ↔ 30 Years
Population:Cisgender Men, Cisgender Women